L-Ornithine Monohydrochloride

L-ornithine monohydrochloride was evaluated in two in vitro genotoxicity and rat 90-day oral toxicity study. No evidence of genotoxicity in the bacterial reverse mutation assay or the chromosomal aberration test in doses up to 5000 micrograms / plate or 1.686 ug / ml, respectively observed both in the presence and absence of activation metabolic. Rats received doses of 0 (basal diet) 1.25%, 2.5% and 5.0%, respectively, for 90 days monohydrochloride L-Ornithine in food. No change in body weight, food consumption, ophthalmoscopy or hematology were observed. temporary increases in water intake and urine volume and decreased specific gravity was observed in the male monohydrochloride 5.0% receiving L-ornithine; However, these were probably due to the central role of ornithine in the urea cycle and the consequent increase of urea production. A decrease in serum chloride concentration and an increase in urine output chloride were observed; However, they were mostly on the administration of ornithine hydrochloride and are not considered by any toxicological significance. No significant results were found at autopsy. Based on the results of the study, a no observed adverse effect level (NOAEL) of 3445 and 3986 mg / kg bw / day was established for male and female rats.

Astilbin introduced in the body can improve kidney

Astilbin is a flavonoid compound from the rhizome of Smilax China L. isolates the effects and possible mechanisms of hyperuricemia and Astilbin nephropathy rats were elucidated in this study. Different doses of astilbin (1.25, 2.5 and 5.0 mg / kg) were administered to rats 10% hyperuricaemic induced by fructose. The results showed that the level of inhibiting uric acid (Uur) and fractional excretion of urate plane (Acta) Astilbin significantly serum urate (Su) reduced, but not by an increase in the xanthine oxidase (XOD ) activity. In addition, the parameters of renal function such as serum creatinine (SCR) and blood urea nitrogen (BUN) were recovered in Astilbin rats hyperuricemia. Other studies have shown that renal damage astilbin prevented against the expression of β1 transforming growth factor (TGF-ß1) and connective tissue growth factor (CTGF), and significant renal protection function by the formation of urate (MSU) inhibiting the production of prostaglandin E₂ (PGE₂) and interleukin-1 (IL-1). These results provide strong evidence for the Astilbin as safe and promising lead in the development of the disease preventing hyperuricemia drug and nephropathy.

Itopride Hydrochloride

Two simple, accurate, reproducible and economical UV spectrophotometry and HPLC method for the simultaneous determination of two components itopride hydrochloride drug mixture and rabeprazole developed from combined as capsule assay. Originally developed method involves the formation and solution of systems of equations at 265.2 nm and 290.8 nm of two wavelengths. Second method is based on two calculating the wavelength was selected wavelengths for estimating itopride hydrochloride 278.0 nm and 298.8 nm and 253.6 nm rabeprazole sodium and 275.2 nm . developed HPLC method is a method in -chromatographisches reverse phase using a Phenomenex C18 column and acetonitrile: phosphate buffer (35:65 v / v), pH 7.0 as mobile phase. All methods developed obey Beer's law used in the concentration range for each method. Assay results have been validated by statistical studies and recovery.
For more, please click:http://www.chemicalspharm.com/New-Products/

What is Kligler Iron Agar

Four screens for rapid detection (4-6 h) Biochemical enteric pathogens isolated media described. The screen consisted of salmonella Kligler iron agar (KIA), urea Tryptophan deamination semisolid medium motility-indole (MIU-TDA) and the o-nitrophenyl-beta-D-galactopyranoside (ONPG) test; Shigella screen consisted of KIA MIU-TDA, the dosage of ONPG and indole test lysine decarboxylation; Yersinia screen consisted of a rhamnose broth; Aeromonas screen consisted of a xylose agar plate. When tested in 2102 and costs 71 screens stock strains correctly detected 212 enteric pathogen isolates (sensitivity, 100%), with a specificity of 98.1%.

Acepromazine maleate

Product Name:Acepromazine maleate

CAS:3598-37-6

Molecular Formula:C23H26N2O5S

Molecular Weight:442.5279

Description:Acepromazine maleate [USAN]; Acepromazine maleate; 10-(3-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone maleate (1:1); 2-Acetyl-10-(3-(dimethylamino)propyl)phenothiazine, maleate; A 23051; Acepromazine monomaleate; Acetylpromazine maleate (1:1); Anatran; Ethanone, 1-(10-(3-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-, (Z)-2-butenedioate (1:1); Maleate acide de l'acetyl 3-dimethylamino 3-propyl-10-phenothiazine; Maleate acide de l'acetyl 3-dimethylamino 3-propyl-10-phenothiazine [French]; NSC 264522; Notensil maleate; Phenothiazine, 2-acetyl-10-(3-(dimethylamino)propyl)-, maleate; Plegicil; Sedalin; Soprontin; UNII-37862HP2OM; Acepromazine hydrogen maleate; Ketone, 10-(3-(dimethylamino)propyl)phenothiazin-2-yl methyl, maleate (1:1); 1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 1-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; maleic acid

From:http://www.chemicals-chemicals.net/Intermediates/Acepromazine-maleate/

For more, please click:http://www.chemicals-chemicals.net/Intermediates/

W(CO)6 for sale

Product Name: W(CO)6
Molecular formula:  W(CO)₆
CAS number: 14040-11-0

Product Description: Colorless odourless volatile solid. Density is 2.65 g/cm³ . Melting point 169 ~ 170 ℃. Sublimation temperature is 50 ℃ . Soluble in ethyl ether, two-a oxygen radicals  ethyl ether and hexane, etc.

Application: For making high purity micro, nano tungsten powder, composite materials, petroleum chemical industry, catalyst, organic synthesis, etc.

Oxymorphone role

Oxymorphone can cause serious or fatal respiratory problems, especially during the first 72 hours after treatment and whenever the dose is increased. Your doctor will monitor you closely during treatment. Tell your doctor if you have or have ever had breathing or asthma idle. Your doctor will probably not take oxymorphone extended release tablets. Also tell your doctor if you have or already have lung diseases such as chronic obstructive pulmonary disease had (COPD, a group of lung diseases, chronic bronchitis and includes emphysema), a head injury, any condition that increases the amount of pressure in the brain, sleep apnea (condition in which breathing stops during sleep or is flat), or kyphoscoliosis (curvature of the spine, which can cause respiratory problems). The risk that you might be more likely to develop breathing problems if you are elderly or weak or malnourished due to the disease. If you experience any of the following symptoms, call your doctor or a received emergency medical treatment: slow breathing, long pauses between breaths, or shortness of breath.